Who Is at Risk:
• A woman's lifetime risk of developing ovarian cancer is 1 in 71, with most cases developing post-menopause.
• Women with close family members — sisters, mothers, aunts, grandmothers — who have had ovarian cancer are at higher risk for developing the disease.
• Women of Eastern European (Ashkenazi) Jewish descent, or women who have the BRCA1 or BRCA2 gene mutation, are at higher risk for ovarian cancer.
• Women who have had breast, colon, or endometrial cancer have an increased risk of developing ovarian cancer.
• Ovarian cancer, sometimes called "the silent killer," is not silent. Symptoms such as bloating, pelvic or abdominal pain, feeling of fullness or urinary issues, can be subtle but are usually present early.
• When symptoms like bloating, abdominal pain, feeling of fullness, or urinary problems are caused by ovarian cancer, they tend to be persistent, and a change from normal.
• Using oral contraceptives, especially over the course of five consecutive years, lowers the risk of ovarian cancer.
• A woman's risk of developing ovarian cancer lowers with every pregnancy.
• Know your family history. Ovarian cancer in the family means an increased risk of ovarian cancer for yourself.
• Approximately 22,000 women in the United States will be diagnosed with ovarian cancer this year.
• Among women in the United States, ovarian cancer is the eighth most common cancer and the fifth leading cause of cancer deaths.
• Currently, there is no reliable method of early detection for ovarian cancer. The mission of the Ovarian Cancer Research Fund is to find one.
About the Ovarian Cancer Research Fund:
• Since 1998, the Ovarian Cancer Research Fund has given over $33 million toward ovarian cancer research.
• The Ovarian Cancer Research Fund's Scientific Advisory Committee, comprised of the nation's top ovarian cancer experts, distributes funding yearly to the most promising up-and-coming researchers in the field.
• Ovarian Cancer Research Fund is the largest private organization in the United States dedicated exclusively to finding a method of early detection, and ultimately a cure, for ovarian cancer.